The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
Opinion|Videos|October 25, 2024
Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC
Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Advertisement
- Please provide an overview of the importance of molecular testing in NSCLC, particularly focusing on ALK rearrangements.
- How has the landscape of ALK testing evolved in recent years, and are there any emerging technologies or approaches that might impact your ability to identify ALK-positive patients?
- What is your approach to first-line treatment selection for ALK-positive disease in patients with NSCLC?
Advertisement
Related to this article
FDA has granted RMAT and fast track designations to celma-cel as a frontline consolidation in large B-cell lymphoma.
The CD70-targeting CAR T cell therapy, ALLO-316, demonstrated encouraging results in previously treated patients with advanced ccRCC.
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.
Advertisement
Advertisement
Trending on OncLive
1
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
2
Oncology Experts Review Key ASCO 2026 Data for Daraxonrasib and Other Novel Therapies in GI Cancers
3
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
4
FDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL
5